Jan. 16, 2025
| Today’s news and insights for biopharma leaders
Deep Dive
Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors and executives interviewed by BioPharma Dive at the J.P. Morgan Healthcare Conference.
|
AbbVie's CEO hinted his company may be less willing to invest in psychiatry, while Lilly explained what it got wrong forecasting GLP-1 drug demand.
|
Q&A
Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his team of dealmakers can juggle them.
|
The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success in diabetes and obesity.
|
Young drugmakers confront several harsh realities this year, among them a contracting sector and competition from China.
|
|
Read this playbook to learn how APPs influence treatment plans and how brands can connect with them to enhance patient journeys and improve results.
|
|
From Our Library
Playbook
Custom content for Avant Healthcare
|
Playbook
Custom content for Storyful
|
Playbook
Custom content for Avant Healthcare
|
Playbook
Custom content for Qiagen
|
Playbook
Custom content for ORO Labs
|
View all resources
| 
